Inspire Medical Systems stock hits 52-week low at 73.91 USD

Inspire Medical Systems Inc.’s stock reached a 52-week low, closing at 73.91 USD. According to InvestingPro analysis, the company maintains a "GREAT" financial health score despite the price decline, suggesting potential undervaluation at current levels. This marks a significant downturn for the company, as its shares have experienced a sharp decline over the past year. The stock has seen a 1-year change of -64.85%, reflecting the challenges faced by the company in maintaining investor confidence amidst market fluctuations. Despite the decline, the company maintains strong fundamentals with a current ratio of 6.14 and minimal debt-to-equity of 0.05. This latest low underscores the volatility in the medical device sector and highlights the need for Inspire Medical Systems to strategize effectively to regain its market position. For deeper insights into INSP’s valuation and 15 additional exclusive ProTips, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Inspire Medical Systems has announced several key developments. The company revealed that its Chief Financial Officer, Rick Buchholz, will step down from his position effective December 31, 2025, to explore other professional opportunities. He will continue in a financial advisory role until February 28, 2026, to ensure a smooth transition. Additionally, Inspire Medical Systems’ Board of Directors has authorized a share repurchase program of up to $200 million, set to run through August 7, 2027. In the realm of analyst ratings, Evercore ISI has initiated coverage on Inspire Medical Systems with an Outperform rating and a price target of $150, citing the company’s strong growth outlook and significant market potential. Meanwhile, Jefferies has adjusted its price target for the company from $205 to $160, maintaining a Buy rating, after the company reported a second-quarter sales beat. KeyBanc has maintained its Sector Weight rating on the stock. These developments reflect ongoing strategic moves and analyst assessments impacting Inspire Medical Systems.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.